Patrick Hughes, co-founder and chief commercial officer of Cluepoints and OSP caught up for an in-person discussion during SCOPE 2024 to find out what developments the company had been working on and how they are benefiting from using AI.
With the pharma and healthcare landscape increasingly being shaped by artificial intelligence (AI), the US Food and Drug Administration (FDA) has taken proactive steps to outline a comprehensive strategy for regulating AI in medical products.
Always the buzz theme at pharma conferences, the subject of artificial intelligence (AI) continues to crop up more and more frequently. Naturally with more and more people using it for work, new regulations on data use and management are starting to appear....
Sepehr Shojaei serves as the vice president of design solutions at Lightship, using his 15 years of experience in clinical research operations to champion a patient-centric approach.
The drug discovery specialist Anagenex has sealed a collaboration pact with Nimbus Therapeutics to co-develop small molecule drugs with the help of artificial intelligence (AI).
OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.
OSP had a discussion with Tracy Curley, CEO of iSpecimen, and Eric Langlois, chief revenue officer of iSpecimen and Michael Howell,founder of Mountaineer Biosciences, Inc. to discuss a number of issues those working in precision medicine still face.
A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.
myTrialsConnect, a research community powered by artificial intelligence (AI) has been launched following a partnership between Elligo Health Research and Avallano.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.
Drug discovery will benefit from a virtual artificial intelligence (AI) expert thanks to Opportunity Pharma and OpenEye, Cadence Molecular Sciences joining forces.
Built upon seven years of real-world patient journey data, Belong.Life has recently announced the launch of its software as a service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.
HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.
The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
The US Food and Drug Administration (FDA) has today (July 31) given clearance via its 510(k) process to one of the artificial intelligence solutions cleared for colonoscopy.
The U.S. startup Readout AI has closed a pre-seed financing round to fuel the development of an artificial intelligence (AI)-based tool to speed up data analysis in clinical trials.
The Israeli company Galmed Pharmaceuticals is deploying artificial intelligence (AI) tools developed by the U.S. company OnKai to help carry out clinical trials of a rare disease treatment in communities that have low access to healthcare.
Everybody seems to be talking about artificial intelligence at the moment. Some are fascinated, others afraid and a few might worry for their jobs. However, for the pharmaceutical industry, it is said to be completely transforming the landscape.
Helmholtz Munich, part of Germany’s biggest research organization, the Helmholtz Association, alongside DDN, the world’s largest data storage company have been selected as a winner of the 2023 AI Breakthrough Awards, for best AI-based solution for life...
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
Aerona Clinical is a medium sized pharmaceutical company, represented not only in the United Kingdom, but in Europe, and with a global reach. The company has been operating in this environment in the pharma industry for 15 to 20 years.
The partners announce that they will combine to use artificial intelligence to improve the identification and enrolment of patients for clinical trials.
Research emerging from the University of Toronto found that using machine learning models was able to guide the design of long-acting drug formulations.
Indegene’s partnership with Tealium leverages AI-driven data strategy for life sciences companies to navigate the industry’s connected technology ecosystem.
OMEC.AI is the first startup to emerge from the alliance of pharma companies and investors that created AION Labs, and will focus on improving the efficacy and safety of drug candidates.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.